Internal Medicine, Medical Oncology · Baltimore, MD
NPI
1124133210
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
227 St Paul Place, 4th Floor
Baltimore, MD, 21202
Phone (410) 783-5858
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.5M
93,280 services
Medicare patients, 2024
1,045
Average age 74
Drug cost, 2024
$1.7M
1,401 prescriptions
Company payments, 2025
$15K
From 34 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David A Riseberg was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 15,300 times for 18 patients. In total David A Riseberg billed 93,280 services in 124 codes, and Medicare paid $1.5M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 15,300 | 18 | $0.26 | $3,958 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 6,900 | 17 | $2.36 | $16K |
| J0897 Injection, denosumab, 1 mg | Office | 6,060 | 51 | $19.04 | $115K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 3,000 | 12 | $0.11 | $344 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,214 | 37 | $0.09 | $110 |
| 99214 Office E&M - Established | Office | 621 | 324 | $95.26 | $59K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 530 | 24 | $0.68 | $362 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 479 | 303 | $13.14 | $6,295 |
| 99214 Office E&M - Established | Facility | 453 | 253 | $69.12 | $31K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 347 | 238 | $13.16 | $4,568 |
| J1750 Injection, iron dextran, 50 mg | Office | 323 | 15 | $13.72 | $4,430 |
| 96375 Injection Administration | Office | 322 | 48 | $12.70 | $4,090 |
| 85025 Blood Count | Office | 264 | 130 | $7.54 | $1,991 |
| 80053 Clinical Chemistry | Office | 236 | 108 | $10.24 | $2,418 |
| 96413 Chemotherapy Administration | Office | 216 | 74 | $106.43 | $23K |
By year: 2022 $1.1M for 92,440 services; 2023 $1.5M for 121,473 services; 2024 $1.5M for 93,280 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 264 | 130 | $7.54 | $1,991 |
| 80053 Clinical Chemistry | 236 | 108 | $10.24 | $2,418 |
| 80048 Clinical Chemistry | 18 | 15 | $8.29 | $149 |
Medicare prescription drug claims, 2024
In 2024, the drug David A Riseberg prescribed most often to Medicare patients was Letrozole, with 624 prescriptions and refills. In total David A Riseberg wrote 1,401 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 624 | 1,768 | 216 | $19K |
| Anastrozole Generic | 153 | 421 | 57 | $2,844 |
| Gabapentin Generic | 47 | 101 | 17 | $792 |
| Tamoxifen Citrate Generic | 38 | 109 | 15 | $1,304 |
| Exemestane Generic | 38 | 110 | 18 | $7,796 |
| Ondansetron Hcl Generic | 36 | 37 | 23 | $221 |
| Oxycodone Hcl Generic | 22 | 22 | Under 11 | $394 |
| Prochlorperazine Maleate Generic | 19 | 19 | 17 | $186 |
| Hydroxyurea Generic | 19 | 53 | Under 11 | $820 |
| Dexamethasone Generic | 19 | 19 | 13 | $314 |
| Ibrance Palbociclib | 18 | 18 | Under 11 | $283K |
| Eliquis Apixaban | 17 | 39 | Under 11 | $23K |
| Nubeqa Darolutamide | 16 | 16 | Under 11 | $217K |
| Duloxetine Hcl Generic | 15 | 35 | Under 11 | $120 |
| Valacyclovir Valacyclovir Hcl | 14 | 31 | Under 11 | $802 |
Brand drugs: 139 claims; generic drugs: 1,262 claims; opioid claims: 47.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David A Riseberg $15K ($15K in general payments such as food, travel and fees and $330 for research) from 34 companies. The largest payer was Gilead Sciences, Inc. with $12K.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 10 | $12K |
| Novartis Pharmaceuticals Corporation NVS | 20 | $1,173 |
| Pfizer Inc. PFE | 4 | $400 |
| Janssen Biotech, Inc. JNJ | 10 | $211 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $170 |
| Caris MPI, Inc. | 2 | $148 |
| Lilly USA, LLC LLY | 4 | $90.47 |
| Genentech USA, Inc. ROG.SW | 4 | $87.26 |
| Genmab U.S., Inc. GMAB | 3 | $83.7 |
| PharmaEssentia USA Corporation 6446.TW | 3 | $78.93 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.